SUZHOU, China, May 25, 2025 -- Innovent Biologics, Inc., a leading biopharmaceutical company, has announced the publication of the results from a Phase 3 clinical study of mazdutide, a dual glucagon $(GCG.UK)$ and glucagon-like peptide-1 (GLP-1) receptor agonist, in The New England Journal of Medicine. The study, GLORY-1, focused on Chinese adults with overweight or obesity and marks a significant advancement in the field of metabolic and endocrine therapies developed in China. This study provides robust clinical evidence for the treatment of overweight and obesity, and it is the first clinical trial of its kind to be published in this prestigious medical journal. Innovent, through strategic collaborations and advanced research, continues to contribute to the goal of 'Healthy China 2030' by promoting science-based weight management solutions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.